Unyango lwe-HIV kunye ne-Isentress (raltegravir)

I-Isentress (ratelgravir) yi- integrase inhibitor -i-class antiretroviral usetyenziso ekwenzeni unyango lwe- HIV . Isentress yinto yokuqala ye-integrase inhibitor yokuvunyelwa yi-US Food and Drug Administration (FDA).

Ngo-Oktobha 2007, bekuvunyelwe ukuba kusetyenziswe abantu abadala abachasene nezinye izidakamizwa ze-antiretroviral . Kodwa ngoJulayi 2009, kwaye emva koko ngoDisemba ka-2011, i-FDA yandise isibonakaliso sayo, ivumela ukuba kusetyenziswe kubo bonke abantu abadala abane-HIV, kunye nabantwana abaneminyaka engama-2-18.

I-Isentress iphakathi kweziyobisi ezicetyiswayo njengendlela yokhetho lokuqala lokukhetha unyango lwe-HIV kwi-US

Ifom

I-Isentress ifumaneka kwiimimiselo ezine ezahlukeneyo:

Ungalokothi utshintshe i-Isentress i-chewables okanye i-suspension yomlomo kwiipilisi zamacwecwe e-Isentress njengoko iifomati zingenayo i-bioequivalent. Sebenzisa kuphela njengoko kuboniswe (jonga iziganeko ezingezantsi).

Imilinganiselo

I-Isentress 400mg, iipilisi ezifakwe kwifilimu kufuneka zimiselwe abadala kunye nabantwana abakhulileyo abanako ukugwinya amaphilisi, ngale ndlela:

Iipilisi ezi-chestable e-Isentress kufuneka zimiselwe kubantwana obunemitha engama-44 (20kg) okanye ngaphezulu abangakwazi ukugwinya amaphilisi, ngale ndlela:

Ukumiswa komlomo we-Isentress okanye iipilisi ezichithwayo kufuneka zimiselwe kubantwana abanesisindo esingama-6,5 (3kg) ukuya kuma-pounds angama-55 (25kg), ngale ndlela:

Ulawulo Lweziyobisi

Isentress ingathathwa kunye okanye ngaphandle kokutya. I-Isentress ayikwazi ukuthathwa yedwa kwaye kufuneka imiselwe njengenxalenye yonyango lwe-antiretroviral (ipirati) .

Iziphumo eziPhakathi

Iziphumo eziqhelekileyo eziqhelekileyo (ezivela kwi-2% okanye ngaphantsi kwamatyala) zi:

Ukungqinelana

Akukho

Ukusebenzisana kweziyobisi

Kucelwa ucebise ugqirha wakho ukuba uthatha nawaphi na a mayeza alandelayo njengoko engakunyanzelwanga ekuphathweni ngokubambisana ne-Isentress kwaye inokuphazamisa ukufumaneka kweziyobisi:

Ukuqwalasela

Izigulane ezithintekayo emva kokuqala i-Isentress maziqhagamshelane nodokotela ngokukhawuleza. Unyango kufuneka ugqitywe kwaye unyango lwezokwelapha lufunwa ukuba i-rash ihamba kunye neentlungu, umsizi okanye intlungu ehlanganyelweyo, i-blisters okanye izilonda, ubomvu okanye ukuvuvukala kwamehlo, ukuvuvukala ubuso okanye umlomo, okanye iingxaki zokuphefumla. Izigulane eziye zafumana ukuphendulwa kwe-hypersensitive kwi-Isentress akufanele ziphinde ziphendulelwe kunye neziyobisi emva kokusombulula iimpawu.

Izifundo zezilwanyana azibonanga ukukhubazeka kokubeleka okanye ukukhulelwa kokubeleka ngexesha lokukhulelwa kwiigundane okanye onogwaja abonakaliswe kwi-Isentress. Nangona kunjalo, impembelelo ye-Isentress kwiintsana ezinamancinci ayikabikwa, kwaye ngenxa yoko, ukuncelisa unceliso alucebisi ukuba oomama bathathe i-Isentress.

Imithombo:

ISebe lezeMpilo kunye neNkonzo zoLuntu (DHHS). "Izikhokelo zokusetyenziswa kwee-Antiretroviral Agents kwi-HIV-1-abadala nabachaphazelekayo." Rockville, Maryland.

FDA. "I-FDA Yandisa Ukusetyenziswa Kwe-HIV Isentress kwaBantwana kunye ne-Adolescents." Silver Spring, eMaryn; Disemba 21, 2011.

Reuters. "UPDATE 2-FDA OKs Ukusetyenziswa Okubanzi kwe-Merck's Isentress yeHIV." Julayi 9, 2009.

US Administration and Drug Administration (FDA). Iphakheji yokuVunywa kweMithi - Igama leMilo: i-Isentress (ratelgravir) i-400mg Tablets. " Silver Spring, eMaryn; Oktobha 12, 2007.